Revefenacin: Completed Phase III enrollment

Theravance completed enrollment in a pair of identical, double-blind, placebo-controlled, U.S. Phase III trials evaluating 88 and 175

Read the full 189 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE